Sara Erridge

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Mark R. Gilbert, Meihua Wang, Kenneth Aldape et al. · Journal of Clinical Oncology · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Pharmacotherapy +14

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 397 citations · Full text

Medicine, Oncology, Pharmacology +17

ESTRO-ACROP guideline “target delineation of glioblastomas”

Maximilian Niyazi, Michael Brada, Anthony J. Chalmers et al. · Radiotherapy and Oncology · 2016 · 382 citations

Medicine, Neurosurgery, Oncology +12

Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma

Michael Brada, Sally Stenning, Rhian Gabe et al. · Journal of Clinical Oncology · 2010 · 248 citations

Medicine, Oncology, Pharmacology +15